Key Points Myriad Genetics is partnering with SOPHiA GENETICS to advance its prostate cancer-specific genomic instability score, or PrGIS, in precision oncology work involving AstraZeneca….
October 08, 2026
Key Points Telix administered the first U.S. commercial doses of Pixclara at medical centers in Indianapolis and Cleveland. Pixclara is the only FDA-approved radiopharmaceutical imaging…
September 18, 2026
Hong Kong Patent Extends bioAffinity’s CyPath Lung Protection in Asia
bioAffinity Technologies (NASDAQ: BIAF) has received a patent in Hong Kong covering CyPath Lung, its noninvasive lung cancer test. The grant follows a Chinese patent…
Key Points Pulse Biosciences completed enrollment of 100 patients in its PRECISE-BTN clinical study. The study is evaluating the nPulse™ Vybrance™ Percutaneous Electrode System for…
September 14, 2026
FDA Approves Telix’s Pixclara for Glioma Brain Cancer Imaging
Key Points The FDA approved Telix Pharmaceuticals’ Pixclara® for PET imaging in patients with glioma, a form of brain cancer. Pixclara is the first FDA-approved…
Key Points AvMEDICAL will market CyPath Lung through its national sales team and established federal procurement network. The agreement targets VA medical centers and other…
bioAffinity Technologies (Nasdaq: BIAF) is highlighting a new clinical framework that explains where CyPath® Lung may fit in the evaluation of pulmonary nodules and ongoing…
Tempus AI (NASDAQ: TEM) just added another rare‑disease data asset to its oncology flywheel, and the stock inched higher on the news. Shares rose about…
Prelude Corporation (PreludeDx), a precision‑diagnostics company focused on early‑stage breast cancer, received FDA Breakthrough Device designation for its AidaBREAST test. This is the company’s second Breakthrough Device;…